Full-Time

Senior Vice President

Global Medical Affairs

Confirmed live in the last 24 hours

Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical

1,001-5,000 employees

Develops therapies for rare genetic diseases

Compensation Overview

$416.8k - $514.8k/yr

+ Bonus + Equity Incentives

Expert

Remote in USA

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a Ultragenyx Pharmaceutical referral from your network.

💡

Applications through a referral are 3x more likely to get an interview!

Requirements
  • M.D. required with minimum 15+ years in biotech/pharma industry in Clinical Drug Development and/or Corporate Medical Affairs.
  • Minimum 12+ years of managing and leading post commercial clinical and medical teams.
  • Previous experience managing a global medical affairs function and/or demonstrated success implementing Medical Affairs program(s) at a biotech/small pharma strongly preferred
  • Product pre-launch/successful launch experience required
  • Demonstrated knowledge of FDA requirements, industry compliance, ISS design and strategies, commercial and publication strategy and medical information processes
  • Working knowledge of current legal and promotional regulatory requirements, demonstrated appreciation of the global compliance landscape
  • Ability to interact and communication with a high degree of professionalism and scientific credibility to the Thought Leader community
  • Ability to establish strong working relationships with a diverse range of internal and external stakeholders to ensure achievement of corporate objectives
  • Possess strong and dynamic leadership skills. Successful and superior influencing skills across all levels of the organization and external collaborators.
  • Ability to travel up to 25%
Responsibilities
  • Lead Medical Affairs strategic input and direction for marketed products globally; provide critical strategic and day-to-day management support in the area of Medical Affairs management. Provide strategic input into the development plans for drugs to support Commercial needs when marketed.
  • Drive creation and oversee execution of the following global strategic plans: Publication Plan, KOL/Advisory Board Plan, Investigator-Initiated Research Plan, and Continuing Medical Education and Grant Plan to optimize the product profile to build product awareness and gain strategic insights for marketing and development strategy.
  • Grow and manage a high-functioning Medical Affairs organization with a focus on staff development and appropriate succession planning. Ensure that company practices are compliant with relevant drug regulations.
  • Provide Medical Affairs leadership to the MSL and PDL teams and overall accountability for the development and management of relationships with Key Opinion Leaders (KOLs). Serve as a senior representative to KOLs, working in collaboration with Senior R&D colleagues similarly involved providing strong medical and scientific presence.
  • Provide strategic leadership and collaboration for Disease strategy plans, abstracts, posters, slides, manuscripts, educational materials, Investigator-Initiated study protocols, Advisory board meeting objectives, Medical information letters, Commercial Brand plans, scientific educational grant requests and patient advocacy grant requests.
  • Serve as a senior representative of Medical Affairs to interact with key internal stakeholders: Commercial, Business Development, Market Access, Clinical Operations, Clinical Sciences, Regulatory, and Program and Portfolio Leadership.
  • Provide medical leadership and support to the Commercial Team to assist in the development and execution of compliant commercial activities; provide Medical Affairs strategic input for the elaboration of the brand plan(s); ensure execution of the Medical Affairs Strategy in line with the Brand Strategy and the execution of compliant Commercial activities.
  • Utilizes medical/scientific, technical, and managerial experience to support research programs, clinical development programs and licensed product maintenance, including developing the strategy for advisory Board and KOL meetings.
Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical

View

Ultragenyx Pharmaceutical develops therapies for rare and ultra-rare genetic diseases, focusing on conditions with limited treatment options. The company has a diverse pipeline of clinical-stage programs, allowing it to address multiple rare diseases simultaneously. Revenue is generated through the sale of FDA-approved therapies like burosumab and UX007, which validate their scientific approach. Ultragenyx aims to transform research into effective treatments while ensuring a consistent supply of medicines for patients.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Novato, California

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • GTX-102 in Phase III trials could lead Ultragenyx in Angelman syndrome treatment.
  • NICE's recommendation of Evkeeza boosts Ultragenyx's market presence in the UK.
  • Setrusumab development opens new therapeutic avenues for bone formation treatments.

What critics are saying

  • Intense competition in Angelman syndrome treatment may impact Ultragenyx's market share.
  • Setrusumab's success is uncertain, facing potential clinical and regulatory challenges.
  • Delays in NICE's recommendation for Evkeeza could affect Ultragenyx's revenue.

What makes Ultragenyx Pharmaceutical unique

  • Ultragenyx focuses on rare and ultra-rare genetic diseases with limited treatment options.
  • The company has a diversified product pipeline addressing multiple rare diseases simultaneously.
  • Ultragenyx's commitment to uninterrupted medicine supply ensures consistent patient treatment.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid Vacation

Volunteer Days

Stock Options

Company Equity

Wellness Program

Professional Development Budget

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
BioSpace
Mar 17th, 2025
Opinion: Angelman Syndrome Race Heats Up Among Ionis, Ultragenyx And Neuren

Several companies are working on new investigational treatments for Angelman syndrome, a rare genetic disorder that affects the nervous system and causes developmental delays, intellectual disability, seizures and speech impairment. Ionis and Ultragenyx are competing to bring investigational antisense oligonucleotide treatments to the market, while Neuren is betting on a synthetic peptide that can be delivered orally. It’s a tight race in a disease space with a high unmet need.Affecting 500,000 to 1 million patients worldwide, Angelman syndrome has no approved disease-modifying treatments. Although antiseizure medication is available, these drugs do not address the root cause, a genetic mutation in the UBE3A gene on chromosome 15. In Angelman syndrome, only the copy of the UBE3A gene inherited from the mother is functional, while the father’s allele is mutated.Both Ionis and Ultragenyx are currently in Phase III trials with their oligonucleotides, called ION582 and GTX-102, respectively. Meanwhile, Neuren is conducting a mid-stage trial on NNZ-2591, a twice-daily oral solution consisting of a synthetic peptide that modulates acetylcholine neurotransmission.Ionis’ ION582 is an investigational intrathecal injection that targets a long noncoding RNA to increase expression of the UBE3A protein in neurons

Arabic Week
Feb 20th, 2025
Global ANGPTL3-lowering therapy market is expected to reach US$ 785.21 million by 2031

Recent Developments In January 2024, Ultragenyx Pharmaceutical Inc. announced that the National Institute for Health and Care Excellence (NICE) has released a final draft guidance recommending Evkeeza (evinacumab) for use within NHS England.

GlobeNewswire
Jan 6th, 2025
Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

NOVATO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) - Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's chief executive officer and president, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 10:30 AM PT.

Stat News
Jan 6th, 2025
The biotech scorecard for the first quarter: 16 stock-moving events to watch

Ultragenyx is developing an antibody treatment for the disease called setrusumab that works by blocking sclerostin, a protein that inhibits bone formation.

TipRanks
Nov 5th, 2024
Ultragenyx Reports Strong Q3 Growth and Milestones

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company dedicated to developing novel therapies for rare and ultra-rare genetic diseases, with a focus on advancing treatments where there are unmet medical needs.